InsiderTrades.com logo

KLRS Insider Trading

Insider Ownership Percentage: 74.99%
Insider Buying (Last 12 Months): $5,000,005.74
Insider Selling (Last 12 Months): $0.00

Kalaris Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Kalaris Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kalaris Therapeutics Share Price & Price History

Current Price: $8.27
Price Change: ▼ Price Decrease of -0.38 (-4.39%)
As of 02/17/2026 05:00 PM ET

This chart shows the closing price history over time for KLRS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Kalaris Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2025Srinivas AkkarajuDirectorBuy479,847$10.42$5,000,005.741,979,847View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Kalaris Therapeutics (NASDAQ:KLRS)

66.05% of Kalaris Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KLRS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Kalaris Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2026ADAR1 Capital Management LLC100,000$0.84M0.1%N/A0.535%Search for SEC Filing on Google Icon
2/17/2026Paradigm Biocapital Advisors LP700,000$5.91M0.2%N/A3.743%Search for SEC Filing on Google Icon
2/16/2026Squarepoint Ops LLC25,367$0.21M0.0%-36.9%0.136%Search for SEC Filing on Google Icon
2/16/2026OMERS ADMINISTRATION Corp30,000$0.25M0.0%N/A0.160%Search for SEC Filing on Google Icon
2/16/2026Barclays PLC6,065$51K0.0%N/A0.032%Search for SEC Filing on Google Icon
2/13/2026Marshall Wace LLP72,876$0.62M0.0%+416.3%0.390%Search for SEC Filing on Google Icon
2/13/2026Walleye Capital LLC11,225$95K0.0%N/A0.060%Search for SEC Filing on Google Icon
2/13/2026Kalehua Capital Management LLC139,901$1.18M1.1%N/A0.748%Search for SEC Filing on Google Icon
2/13/2026Alyeska Investment Group L.P.403,551$3.40M0.0%N/A2.158%Search for SEC Filing on Google Icon
2/13/2026Siren L.L.C.435,798$3.68M0.1%+36.9%2.330%Search for SEC Filing on Google Icon
2/13/2026State Street Corp25,410$0.21M0.0%+12.4%0.136%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC33,114$0.28M0.0%N/A0.177%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC87,751$0.74M0.0%-22.2%0.469%Search for SEC Filing on Google Icon
2/12/2026Keel Point LLC10,225$86K0.0%N/A0.055%Search for SEC Filing on Google Icon
2/11/2026Propel Bio Management LLC42,053$0.36M0.3%N/A0.225%Search for SEC Filing on Google Icon
2/10/2026Goldman Sachs Group Inc.34,303$0.29M0.0%+52.7%0.183%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC82,647$0.70M0.0%+28.0%0.442%Search for SEC Filing on Google Icon
2/9/2026Simplify Asset Management Inc.20,074$0.17M0.0%N/A0.107%Search for SEC Filing on Google Icon
2/6/2026Nano Cap New Millennium Growth Fund L P4,000$34K0.0%N/A0.021%Search for SEC Filing on Google Icon
2/5/2026WHI TRUST Co LLC97,493$0.82M0.6%N/A0.521%Search for SEC Filing on Google Icon
11/17/2025Woodline Partners LP241,102$1.39M0.0%N/A1.289%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC24,923$0.14M0.0%-53.9%0.133%Search for SEC Filing on Google Icon
11/14/2025Bridgeway Capital Management LLC22,500$0.13M0.0%N/A0.120%Search for SEC Filing on Google Icon
11/14/2025Squarepoint Ops LLC40,173$0.23M0.0%-32.0%0.215%Search for SEC Filing on Google Icon
11/13/2025Johnson Financial Group Inc.10,000$58K0.0%N/A0.053%Search for SEC Filing on Google Icon
11/3/2025Belpointe Asset Management LLC40,000$0.23M0.0%N/A0.214%Search for SEC Filing on Google Icon
10/31/2025Fortis Capital Advisors LLC40,000$0.23M0.0%N/A0.214%Search for SEC Filing on Google Icon
8/15/2025Octagon Capital Advisors LP360,000$0.96M0.2%-25.2%1.925%Search for SEC Filing on Google Icon
8/14/2025Gilead Sciences Inc.317,789$0.85M0.1%-56.1%1.699%Search for SEC Filing on Google Icon
8/12/2025XTX Topco Ltd24,234$65K0.0%N/A0.130%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kalaris Therapeutics logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Read More on Kalaris Therapeutics

Today's Range

Now: $8.27
Low: $8.08
High: $9.96

50 Day Range

MA: $9.10
Low: $7.57
High: $10.42

52 Week Range

Now: $8.27
Low: $2.14
High: $12.90

Volume

176,657 shs

Average Volume

43,999 shs

Market Capitalization

$154.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Kalaris Therapeutics?

Kalaris Therapeutics' top insider shareholders include:
  1. Srinivas Akkaraju (Director)
Learn More about top insider investors at Kalaris Therapeutics.

Who are the major institutional investors of Kalaris Therapeutics?

Kalaris Therapeutics' top institutional investors include:
  1. Paradigm Biocapital Advisors LP — 3.74%
  2. Siren L.L.C. — 2.33%
  3. Alyeska Investment Group L.P. — 2.16%
  4. Kalehua Capital Management LLC — 0.75%
  5. ADAR1 Capital Management LLC — 0.53%
  6. WHI TRUST Co LLC — 0.52%
Learn More about top institutional investors of Kalaris Therapeutics stock.

Which institutional investors are selling Kalaris Therapeutics stock?

During the last quarter, KLRS stock was sold by these institutional investors:
  1. Renaissance Technologies LLC
  2. Squarepoint Ops LLC

Which institutional investors are buying Kalaris Therapeutics stock?

During the last quarter, KLRS stock was acquired by institutional investors including:
  1. Paradigm Biocapital Advisors LP
  2. Alyeska Investment Group L.P.
  3. Kalehua Capital Management LLC
  4. Siren L.L.C.
  5. ADAR1 Capital Management LLC
  6. WHI TRUST Co LLC
  7. Marshall Wace LLP
  8. Propel Bio Management LLC